TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00022737
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00022737
Drug: mercaptopurine tablet
Normalized name: Mercaptopurine Tablets
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00022737
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, and orally
Study: NCT00003483
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00180908
Drug: Etoposide, Ifosfamide, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00180908
Drug: Doxorubicin, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02280876
Drug: 1 - Andrographis paniculata p/st extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile.
Study: NCT04744753
Drug: Calcium Ionophore A23187
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF.
Study: NCT00288002
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00288002
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01584830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given 3 weeks on/1 week off (160 mg od po.)
Study: NCT00972322
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to MK-8245 twice daily for 28 days
Study: NCT02251249
Drug: Paracetamol concentration time curve from 0 to 120 min
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
Study: NCT00135473
Drug: 10% Hemohes® (10% Hydroxyethyl starch)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00135473
Drug: Sterofundin® (Ringer lactate solution)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00135473
Drug: Actrapid® (Insulin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01836939
Drug: TSO 2500
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
Study: NCT03108963
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
Study: NCT01836939
Drug: TSO 7500
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
Study: NCT01372839
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Study: NCT01225380
Drug: GS-9190 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching GS-9190 capsule BID, 24 weeks
Study: NCT01225380
Drug: Copegus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
Study: NCT01429506
Drug: Intensive medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
Study: NCT04358432
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT01042938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
Study: NCT03325790
Drug: 200mg SPI-1005 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active: low dose
Study: NCT03231124
Drug: LEO 32731
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 32731 is being developed by LEO Pharma.
Study: NCT03231124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same excipients in the same concentration, only lacking LEO 32731
Study: NCT04387539
Drug: SOF/SMV/DCV/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
Study: NCT04144712
Drug: Caffeine Citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: study rate of occurrence of Apnea of Prematurity between the 2 groups
Study: NCT03285607
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Standard of care
Study: NCT03285607
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Standard of care
Study: NCT01251770
Drug: 0.45% NaCl/dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.
Study: NCT01251770
Drug: 0.3% NaCl/dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.
Study: NCT01355874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment BID for 14 days during double blind.
Study: NCT02412735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control solution
Study: NCT01287325
Drug: DNK333 100 mg twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01287325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00633269
Drug: AZD2281
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Oral Dose
Study: NCT03405090
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer
Study: NCT03176264
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg every 4 weeks
Study: NCT03176264
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
Study: NCT01508949
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Study: NCT00230750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo.
Study: NCT00941278
Drug: PH-10 (0.001% Rose Bengal)
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study: NCT02838628
Drug: 50 mg of KX2-391 Ointment 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 50 mg; Route of administration: Topical
Study: NCT01008553
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
Study: NCT01008553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
Study: NCT02547571
Drug: High volume PEG split-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Study: NCT02547571
Drug: Low volume PEG split-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
Study: NCT02547571
Drug: High volume PEG non split, day before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
Study: NCT02847429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02547571
Drug: Low volume PEG non split, same day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
Study: NCT00224523
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00241488
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01720576
Drug: REGN1033 (SAR391786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01720576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03257995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing no active ingredients delivered via Concept1 device
Study: NCT03422575
Drug: Etoricoxib 120Mg Film-coated Tablet
Normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
Study: NCT03422575
Drug: Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
Study: NCT01022541
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above.
Study: NCT04320615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Study: NCT03559062
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
Study: NCT03559062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to TEZ/IVA FDC
Study: NCT02349152
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
Study: NCT02349152
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
Study: NCT03272503
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical matching placebo lactose tablets
Study: NCT01218347
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg once daily for 21 days
Study: NCT03903718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
Study: NCT01594827
Drug: Placebo (Sterile Water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Study: NCT01594827
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. \>45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day
Study: NCT02677870
Drug: saproterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The drug will be given as described in the arm/group descriptions.
Study: NCT01100606
Drug: EUR-1008 (APT-1008)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
Study: NCT01100606
Drug: EUR-1008 (APT-1008)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
Study: NCT02658877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
Study: NCT03638076
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
Study: NCT00346905
Drug: Enteryx
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03120468
Drug: Topiramate and N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
Study: NCT04366713
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
Study: NCT02406209
Drug: NS2
Normalized name: NS2B-3 proteinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS2 ophthalmic drops (0.5%)
Study: NCT02406209
Drug: Prednisolone acetate ophthalmic suspension (1%)
Normalized name: prednisolone acetate Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03251560
Drug: Fuke Qianjin capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuke Qianjin capsule 0.8g pills by mouth, three times daily
Study: NCT03251560
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule 0.8g pill by mouth, three times daily
Study: NCT03331627
Drug: STR001-IT and STR001-ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: STR001-IT intrataympanic injection and STR001-ER tablet
Study: NCT00335140
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
Study: NCT00335140
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture
Study: NCT03901716
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Group S received sufentanil 0.1 mcg/kg.
Study: NCT03901716
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in Group F received fentanyl 1 mcg/kg.
Study: NCT03901716
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.
Study: NCT03738475
Drug: TIMP-GLIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
Study: NCT03738475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously on days 1 and 8.
Study: NCT00852137
Drug: PEP005 (ingenol mebutate) Gel, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
Study: NCT01384162
Drug: sNN0029
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICV infusion
Study: NCT02470780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Rifaximin treatment.
Study: NCT01023958
Drug: BI 6727, IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: phase II
Study: NCT04334512
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with azithromycin
Study: NCT00742326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule daily
Study: NCT00852137
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel once daily for 2 consecutive days
Study: NCT00922688
Drug: Dipeptide Alanyl-Glutamine
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
Study: NCT00922688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
Study: NCT00922688
Drug: Dipeptide Alanyl-Glutamine
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
Study: NCT01244139
Drug: BIIB033
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
Study: NCT01244139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion dummy drug
Study: NCT02268994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00108251
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aldosterone receptor blocker
Study: NCT00108251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02635893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill will be administered instead of medication by mouth